You are currently viewing a new version of our website. To view the old version click .
Current Oncology
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
  • Article
  • Open Access

1 April 2008

The Role of DNA Hypermethylation and Demethylation in Cancer and Cancer Therapy

Department of Pharmacology and Therapeutics, Moshe Szyf, McGill University, McIntyre Medical Building, 3655 Promenade Sir-William-Osler, Montreal, QC H3G 1Y6, Canada

Abstract

Methylation of DNA is known to be an important mechanism of gene regulation. A hallmark of cancer is the deregulation of the DNA methylation machinery and aberrant DNA methylation patterns 1. In vertebrate genomes, a large fraction of the CG dinucleotide sequence is modified by methylation in gene- and tissuespecific patterns 2. Methylation of critical regulatory regions silences gene expression; loss of methylation is associated with gene activation 3. Because cancer progression requires many changes in the normal program of gene expression, it stands to reason that aberrations in DNA methylation play a critical role in the changes in gene expression involved in cancer progression and metastasis. Methylation changes in DNA play a role very similar to that of genetic mutations in cancer; however, unlike a genetic alteration, DNA methylation is potentially reversible with pharmacologic intervention. The DNA methylation machinery was therefore proposed—almost a decade and a half ago—to be an attractive anticancer target 4.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.